N
DYN icon

Nuveen’s Dyne Therapeutics DYN Stock Holding History

Nuveen’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13M Buy
718,333
+97,023
+16% +$1.67M ﹤0.01% 1401
2025
Q4 		$12.2M Buy
621,310
+276,413
+80% +$5.23M ﹤0.01% 1443
2025
Q3 		$4.36M Buy
344,897
+145,066
+73% +$1.65M ﹤0.01% 1971
2025
Q2 		$1.9M Sell
199,831
-23,384
-10% -$257K ﹤0.01% 2325
2025
Q1 		$2.33M Sell
223,215
-43,189
-16% -$618K ﹤0.01% 2277
2024
Q4 		$6.28M Sell
266,404
-10,010
-4% -$296K ﹤0.01% 1878
2024
Q3 		$9.93M Sell
276,414
-357,222
-56% -$14.2M ﹤0.01% 1613
2024
Q2 		$22.4M Buy
633,636
+98,875
+18% +$2.87M 0.01% 1059
2024
Q1 		$15.2M Buy
534,761
+384,432
+256% +$8.69M ﹤0.01% 1341
2023
Q4 		$2M Buy
150,329
+2,453
+2% +$24K ﹤0.01% 2413
2023
Q3 		$1.32M Sell
147,876
-1,097
-0.7% -$11.8K ﹤0.01% 2460
2023
Q2 		$1.68M Buy
148,973
+14,360
+11% +$169K ﹤0.01% 2429
2023
Q1 		$1.55M Sell
134,613
-11,168
-8% -$145K ﹤0.01% 2438
2022
Q4 		$1.69M Sell
145,781
-15,885
-10% -$184K ﹤0.01% 2467
2022
Q3 		$2.05M Sell
161,666
-39,022
-19% -$447K ﹤0.01% 2391
2022
Q2 		$1.38M Buy
200,688
+57,863
+41% +$399K ﹤0.01% 2629
2022
Q1 		$1.28M Buy
142,825
+2,882
+2% +$24.5K ﹤0.01% 2706
2021
Q4 		$1.66M Sell
139,943
-5,835
-4% -$82K ﹤0.01% 2655
2021
Q3 		$2.37M Sell
145,778
-5,953
-4% -$106K ﹤0.01% 2592
2021
Q2 		$3.19M Buy
151,731
+110,223
+266% +$2.07M ﹤0.01% 2484
2021
Q1 		$644K Buy
41,508
+18,190
+78% +$352K ﹤0.01% 3033
2020
Q4 		$490K Buy
+23,318
New +$461K ﹤0.01% 3047

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Nuveen's DYN Position: Q1 2026 in Review

Nuveen increased its Dyne Therapeutics (DYN) stake by 16% in Q1 2026, buying an estimated $1.67M and bringing the position to 718,333 shares worth $13M. The position accounts for ﹤0.01% of the portfolio, ranked #1401.

Nuveen first reported a position in DYN in Q4 2020 and has held it in 22 quarters since. The position peaked at $22.4M in Q2 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Nuveen held 718,333 shares of Dyne Therapeutics worth $13M as of Q1 2026.
  • Nuveen bought 97,023 Dyne Therapeutics shares in Q1 2026, an estimated $1.67M.
  • Dyne Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #1401 holding.
  • Nuveen first reported a position in Dyne Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Nuveen's Dyne Therapeutics position peaked at $22.4M in Q2 2024.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.